Session: T-Cell Responses in Adults

Home

Session 40 Poster Abstracts
T-Cell Responses in Adults
Monday, 1:30 - 3:30 pm
Poster Hall


200	Novel and Promiscuous CD8⁺ T-cell Epitopes in Conserved Regions of Subtype C Gag Recognized by HIV-1-infected Southern Africans A Masemola, G Khoury, T Mashishi, M Paximadas, A Puren, and C Gray Natl. Inst. for Communicable Diseases, Johannesburg, South Africa*
201	Maintenance and Expansion of Mucosal CD8⁺ CTL in HIV-1 Infection Y Ding¹, J Cao¹, C Galloway², D Berger², J P McNevin², G Diaz¹, P Nelson², and M J McElrath^1,2 ¹Fred Hutchinson Cancer Res. Ctr., Seattle, WA, USA and ²Univ. of Washington, Seattle, USA*
202	Beyond Help: Direct Effector Functions of HIV-1-Specific CD4⁺ T Cells P Norris¹, H Moffett¹, O Yang², D Kaufmann¹, M Addo¹, B D Walker¹, and E Rosenberg¹ ¹Massachusetts Gen. Hosp., Boston, MA, USA and ²Geffen Sch. of Med., Univ. of California, Los Angeles Med. Ctr., USA.*
203	Identification of Circulating Antigen-specific CD4⁺ T Lymphocytes with a CCR5⁺, Cytotoxic Phenotype in an HIV-1 Long-term Non-progressor, and in CMV Infection J Zaunders*¹, W Dyer², B Wang³, M L Munier⁴, R Newton⁵, J Moore¹, M Miranda-Saksena³, C Mackay⁵, D A Cooper⁴, N K Saksena³, and A D Kelleher⁴ ¹St. Vincent's Hosp., Sydney, Australia; ²Australian Red Cross Blood Svc., Sydney, Australia; ³Westmead Millennium Inst., Sydney, Australia; ⁴St. Vincent's Hosp. and Univ. of New South Wales, Sydney, Australia; and ⁵Garvan Inst. of Med. Res., Sydney, Australia
204	Cytokine Profiles of T-cell Responses Induced by Vaccines and Natural Infection S C De Rosa, S P Perfetto, R Bailer, L Lamoreaux, R Koup, and M Roederer Vaccine Res. Ctr., NIAID, NIH, DHHS, Bethesda, MD, USA*
205	Evaluation of an Antigen-recognizing CD8⁺ T-cell Population: Relevance of CD4^dimCD8^bright T Cells to HIV Pathogenesis A Zloza¹, E Connick², A Landay¹, and L Al-Harthi¹ ¹Rush Univ. Med. Ctr., Chicago, IL, USA and ²Univ. of Colorado Hlth. Sci. Ctr., Denver, USA*
206	Phospho-proteomic Flow Cytometry Signatures of HIV-1 Infection Reveals Early Perturbations in T Cell Activation J-F Fortin, and G P Nolan Baxter Lab. for Genetic Pharmacology, Stanford Univ., CA, USA*
207	Antigenic Presentation by HIV-1 Bearing Peptide-Loaded Class II Major Histocompatibility Complex (MHC) Molecules Induces NF-kB and NFAT in Human CD4⁺ T Lymphocytes J Roy, G Martin, J-F Giguère, D Bélanger, M Pétrin, S Bounou, and M J Tremblay Laval Univ., Ste-Foy, Canada*
208	Expansions of Distinct Vbeta Populations in HIV Infected Patients Do Not Secrete IFN-gamma ex vivo after Stimulation with HIV Peptides D Meyer-Olson*^1,2, M Altfeld¹, K W Brady³, R Dranert¹, T M Allen¹, M M Addo¹, D Strick¹, E S Rosenberg¹, B D Walker¹, and S A Kalams³ ¹Partners AIDS Res. Ctr., Massachusetts Gen. Hosp., Harvard Med. Sch., Boston, USA; ²Zentrum Innere Medizin, Medizinische Hochschule Hannover, Germany; and ³Vanderbilt Univ. Med. Ctr., Nashville, TN, USA
209	Modulation of CTL Differentiation by Cell Division J Yu, H-Y Chen, J Cano, R Reichman, and X Jin Univ. of Rochester, NY, USA*
210	Heterogeneity of Functionally Distinct Populations of CD8 T Cells in Human Virus Infections S C Zimmerli, A Harari, F Vallelian, and G Pantaleo Lab. of AIDS Immunopathogenesis, Lausanne, Switzerland*
211	The Ratio of CD28 Expression on CD4⁺ T-cells to HLA-DR CD38 Expression on CD8⁺ T-cells Is a Predictor of Functional Immune Responses in Chronic HIV-1-infection C Lange*¹, H Valdez^2,3, S Sieg², J Gibney², B Rodriguez², K Medvik², R Asaad², and M Lederman² ¹Ctr. for AIDS Res., Case Western Reserve Univ., Cleveland, OH, USA and Med. Clin., Res. Ctr. Borstel, Germany; ²Ctr. for AIDS Res., Case Western Reserve Univ., Cleveland, OH, USA; and ³Boehringer Ingelheim Inc., USA
212	Generation of Dysfunctional CD8⁺ T Cells in the Setting of HIV Infection D Favre¹, C Stoddart¹, R Hoh², J Martin², S Deeks², and J M McCune^1,2 ¹Gladstone Inst. of Virology and Immunology, San Francisco, CA, USA and ²Univ. of California, San Francisco, USA*
213	Increased Immune Activation Is Associated with Decreased Responsiveness to in vivo IL-2 Administration I Sereti¹, P Sklar², M Ramchandani¹, V Natarajan³, J Metcalf¹, S Wynne¹, R Davey¹, J Kovacs⁴, and H C Lane¹ ¹NIAID, NIH, DHHS, Bethesda, MD, USA; ²Drexel Univ., Philadelphia, PA, USA; ³SAIC, Frederick, MD, USA; and ⁴CCMD, NIH, Bethesda, MD, USA*
214	Viral Infection Persistence but not Level of Virimia Leads to Ablation of HIV-Specific CD4 and CD8 T Cells B Yassine-Diab¹, A-El Kernaleguen¹, S Younes¹, R Boulassal², D Rouleau³, J-P Routy², C Tremblay⁴, and R-P Sékaly¹ ¹Univ. of Montreal, Quebec, Canada; ²McGill Univ., Montreal, Quebec, Canada; ³CHUM, Campus Notre-Dame, Montreal, Canada; and ⁴CHUM,Campus St-Luc, Montreal, Canada*
215	Diminished CD4⁺ E Speelmon^1,2, A Desbien², D Livingston-Rosanoff², and M J McElrath^1,2 ¹Univ. of Washington, Seattle, USA and ²Fred Hutchinson Cancer Res. Ctr., Seattle, WA, USA*